Global Small Molecule API Market 2026 – Industry Analysis, size, share and Trend
A
Small molecule Active Pharmaceutical Ingredient (API) is
a low molecular weight organic compound, which may help to control
biological process, with a size on the order of 1 nm. Most
of the small molecule can be administered orally and are most likely
to be absorbed by the body. Owing to its small size it has properties
of rapid diffusibility to reach at intracellular site of action.
Small Molecule API Market – Dynamics
The small molecule API market is witnessing rapid
growth due to increasing number of corporate agreements. For
instance, BASF Pharma will sell its OMEGA 3 manufacturing facility in
Norway to Marine Ingredients. The Highly Potent Active Pharmaceutical
Ingredients (HPAPI) is projected to witness high growth rate, owing
to easy access to the people for medication in emerging economies.
The rising prevalence of diseases such as cancer, cardiovascular, and
infectious diseases is expected to propel demand for manufacturing of
small molecule APIs. According to the National Center for
Biotechnology Information (NCBI) report, in 2014, out of 570,341
deaths 29.4% were due to cancer and 27.1% were due to cardiovascular
disease. Increasing consumer awareness, benefits of small molecule
API, expiry of patents covering the top-selling pharmaceuticals, and
technological advancement in manufacturing sector are expected to
drive the market growth over the forecast period. Increasing adoption
of generic drugs has resulted into affordable healthcare expenditure,
which is expected to increase production of small molecule API’s,
in turn driving the global small molecule API market growth.
According to the Indian Brand Equity Foundation (IBEF), in 2018,
India is largest producer of generic medicines, which supplies 50% of
vaccines and 40% of drugs to the U.S. and 25% of drugs to the U.K.
Small Molecule API Market – Regional
insights
North America held the largest market share for
small molecule API registering for 38.84% in 2017, due to high
adoption rate of accelerated regulatory review of innovative
medicines. Asia Pacific excluding Japan (APEJ) market is estimated to
witness rapid growth in market, owing to high adoption of over the
counter (OTC) drugs by large patient population coupled with growing
healthcare and pharmaceutical industry and strong research and
development in API. According to IBEF, investment in research and
development by Indian pharmaceutical companies increased (in term of
sales) from 5.3% to 8.5% from 2012 to 2018.
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2423
Small Molecule API Market – Competitive
landscape
The major player operating in global small
molecule API market include ALLERGAN, Aurobindo Pharma, Cambrex
Corporation, Albemarle Corporation, D.r. Reddy’s Laboratories Ltd.
The other key players in market are Johnson Matthey, Siegfried
Holding AG, Pfizer, Sanofi S.A., Novartis AG, Johnson & Johnson,
Bristol-Myers Squibb, Bachem Holding AG, Boehringer Ingelheim GmbH,
F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, GILEAD Science Inc.,
Albany Molecular Research Inc., Sun Pharmaceuticals, AstraZeneca,
Merck & Co, Inc., BASF SE, and Teva Pharmaceuticals. In
March 2012, the FDA approved Ilumya (Tildrakizumab-asmn) developed by
Sun Pharmaceuticals used for Plaque Psoriasis.
About Coherent Market Insights
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702


Comments
Post a Comment